ImmunoTherapeutics, Inc. Changes Name to Endorex Corporation; New Ticker Symbol for Common Stock: ENDU.FARGO, N.D.--(BUSINESS WIRE)--September 9, 1996--ImmunoTherapeutics, Inc. today announced that, effective immediately, it has changed its name to Endorex Corporation following approval by a majority of shareholders at its annual meeting held on August 8, 1996. In coordination with the Nasdaq OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. , the Company's publicly traded securities have been allocated new ticker symbols that more closely correspond with the Company's new name. The Company's common stock, previously traded as IMNP (OTC Bulletin Board: IMNP), is now trading under the symbol ENDU. The Company's units, previously traded under the symbol IMPU IMPU Information Processing and Management of Uncertainty IMPU Inner Mongolia Polytechnic University IMPU IP Multimedia Public Identity IMPU IM Public identity IMPU Improved Module Processor Unit IMPU Indian Medical Promotion Unit , are now trading under the symbol ENDUU. The Company's warrants, which expire on August 13, 1997, and previously traded under the symbol IMPW, now trade under the symbol ENDUW. Dr. Gerald Vosika, Chairman, said "The Company's new name, Endorex, stems from the word endothelium endothelium /en·do·the·li·um/ (-the´le-um) pl. endothe´lia the layer of epithelial cells that lines the cavities of the heart, the serous cavities, and the lumina of the blood and lymph vessels. , the tissue from which the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. is derived, and to a large number of the cell types to which the Company's therapeutic are directed." "The name Endorex better reflects the diversity of products the Company is developing to increase and/or modify the endogenous immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. of individuals to cancer and infectious diseases," said Michael Rosen, President and Chief Executive Officer. Endorex Corporation is a biotechnology company involved in the research, development and clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy of immunopharmaceuticals for the prevention and treatment of cancer and infectious diseases. The Company was founded in 1985 to develop synthetic and natural products that activate and/or enhance the immune system, either directly or through the induction of biologically active mediators. CONTACT: Robinson Lerer & Montgomery Mary Ann Dunnell, 212-484-7797 or Endorex Corporation Michael Rosen, 847-604-9575 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion